EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study

Antonios Douros, Ying Cui, Robert W Platt, Kristian B Filion, Giada Sebastiani, Christel Renoux

Thrombosis Research · 2024

DOI: 10.1016/j.thromres.2024.03.024 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thrombosis Research, 2024. Verfasst von Antonios Douros und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada; Department of Medicine, McGill Univer…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Liver Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de Recherche du Québec - Santé, McGill University, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: The effects of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) and liver disease remain poorly understood. Our multinational cohort study assessed the effectiveness and safety of DOACs in this high-risk population. METHODS: We assembled two population-based cohorts in United Kingdom and in Québec of NVAF patients with liver disease initiating DOACs or vitamin K antagonists (VKAs) between 2011 and 2020. Using an as-treated exposure definition, we compared DOACs to VKAs and apixaban to rivaroxaban. After inverse probability of treatment weighting, Cox proportional hazards models estimated site-specific hazard ratios (HRs) and 95 % confidence intervals (CIs) of ischemic stroke and major bleeding. Site-specific estimates were pooled using random-effects models. Analyses were repeated among NVAF patients with cirrhosis. RESULTS: There were 11,881 NVAF patients with liver disease (2683 with cirrhosis). Among those, 8815 initiated DOACs (4414 apixaban, 2497 rivaroxaban) and 3696 VKAs. The HRs (95 % CIs) for DOACs compared to VKAs were 1.01 (0.76-1.34) for ischemic stroke and 0.87 (0.77-0.99) for major bleeding. Results were consistent among patients with cirrhosis. The HRs (95 % CIs) for apixaban compared to rivaroxaban were 0.85 (0.60-1.20) for ischemic stroke and 0.80 (0.68-0.95) for major bleeding. This decreased bleeding risk was not observed among patients with cirrhosis (HR, 1.01; 95 % CI 0.72-1.43). CONCLUSIONS: Among NVAF patients with liver disease, DOACs were as effective and slightly safer than VKAs, and apixaban was as effective but safer than rivaroxaban. The safety benefit with apixaban was not present among patients with cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationLiver DiseasesHumansFemaleMaleAgedCohort StudiesAdministration, OralAnticoagulantsMiddle AgedHemorrhageRivaroxabanFactor Xa InhibitorsPyridonesPyrazolesAged, 80 and over

Stichwörter der Autor:innen

AnticoagulationAntithrombotic treatmentCardiovascular diseaseHepatic disease

Substanzen

AnticoagulantsRivaroxabanapixabanFactor Xa InhibitorsPyridonesPyrazoles

Autor:innen und Institutionen

  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada; Department of Medicine, McGill University, Montreal, Québec, Canada; Centre for Clinical Epidemiology, Lady…
  • Centre for Clinical Epidemiology, Lady Davis Institute, Montreal, Québec, Canada.
  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada; Centre for Clinical Epidemiology, Lady Davis Institute, Montreal, Québec, Canada; Department of Pediatrics,…
  • Department of Medicine, McGill University, Montreal, Québec, Canada; Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Québec, Canada.

Förderung

  • Fonds de Recherche du Québec - Santé
  • McGill University
  • Canadian Institutes of Health Research

Zitieren

APA

Douros, A., Cui, Y., Platt, R. W., Filion, K. B., Sebastiani, G., & Renoux, C. (2024). Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study. Thrombosis Research. https://doi.org/10.1016/j.thromres.2024.03.024

Vancouver

Douros A, Cui Y, Platt RW, Filion KB, Sebastiani G, Renoux C. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study. Thrombosis Research. 2024. doi:10.1016/j.thromres.2024.03.024

BibTeX
@article{Douros2024,
  author = {Douros, Antonios and Cui, Ying and Platt, Robert W and Filion, Kristian B and Sebastiani, Giada and Renoux, Christel},
  title = {Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study},
  journal = {Thrombosis Research},
  year = {2024},
  doi = {10.1016/j.thromres.2024.03.024}
}
Kostenlos starten →